Mesoblast Ltd (MSB) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.027x

Based on the latest financial reports, Mesoblast Ltd (MSB) has a cash flow conversion efficiency ratio of -0.027x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-15.56 Million ≈ $-11.01 Million USD) by net assets (AU$574.68 Million ≈ $406.63 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MSB defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Mesoblast Ltd - Cash Flow Conversion Efficiency Trend (2005–2025)

This chart illustrates how Mesoblast Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Mesoblast Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Mesoblast Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
C*Core Technology Co Ltd
SHG:688262
0.051x
CETC Digital Technology Co Ltd
SHG:600850
0.020x
Freehold Royalties Ltd.
TO:FRU
0.055x
NOS S.G.P.S. S.A.
LS:NOS
0.145x
NagaCorp Ltd
F:N9J
0.028x
The Jammu & Kashmir Bank Limited
NSE:J&KBANK
-0.278x
China Marine Information Electronics Co Ltd
SHG:600764
0.018x
NCR Atleos Corporation
NYSE:NATL
0.442x

Annual Cash Flow Conversion Efficiency for Mesoblast Ltd (2005–2025)

The table below shows the annual cash flow conversion efficiency of Mesoblast Ltd from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Mesoblast Ltd.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$597.44 Million
≈ $422.73 Million
AU$-49.95 Million
≈ $-35.35 Million
-0.084x +17.12%
2024-06-30 AU$480.36 Million
≈ $339.88 Million
AU$-48.46 Million
≈ $-34.29 Million
-0.101x +19.98%
2023-06-30 AU$501.84 Million
≈ $355.08 Million
AU$-63.27 Million
≈ $-44.77 Million
-0.126x +4.74%
2022-06-30 AU$497.04 Million
≈ $351.69 Million
AU$-65.78 Million
≈ $-46.54 Million
-0.132x +27.87%
2021-06-30 AU$581.40 Million
≈ $411.38 Million
AU$-106.68 Million
≈ $-75.48 Million
-0.183x -78.83%
2020-06-30 AU$549.33 Million
≈ $388.68 Million
AU$-56.37 Million
≈ $-39.88 Million
-0.103x +14.59%
2019-06-30 AU$481.05 Million
≈ $340.37 Million
AU$-57.79 Million
≈ $-40.89 Million
-0.120x +12.56%
2018-06-30 AU$546.01 Million
≈ $386.34 Million
AU$-75.01 Million
≈ $-53.08 Million
-0.137x +25.64%
2017-06-30 AU$516.77 Million
≈ $365.64 Million
AU$-95.47 Million
≈ $-67.55 Million
-0.185x -10.89%
2016-06-30 AU$528.16 Million
≈ $373.71 Million
AU$-88.00 Million
≈ $-62.26 Million
-0.167x +16.58%
2015-06-30 AU$609.36 Million
≈ $431.16 Million
AU$-121.71 Million
≈ $-86.12 Million
-0.200x -39.49%
2014-06-30 AU$571.72 Million
≈ $404.53 Million
AU$-81.86 Million
≈ $-57.92 Million
-0.143x -66.87%
2013-06-30 AU$630.27 Million
≈ $445.95 Million
AU$-54.08 Million
≈ $-38.27 Million
-0.086x +43.03%
2012-06-30 AU$478.85 Million
≈ $338.82 Million
AU$-72.12 Million
≈ $-51.03 Million
-0.151x -171.78%
2011-06-30 AU$515.84 Million
≈ $364.99 Million
AU$108.23 Million
≈ $76.58 Million
0.210x +182.38%
2010-06-30 AU$37.92 Million
≈ $26.83 Million
AU$-9.66 Million
≈ $-6.83 Million
-0.255x +28.89%
2009-06-30 AU$25.79 Million
≈ $18.25 Million
AU$-9.24 Million
≈ $-6.54 Million
-0.358x -51.39%
2008-06-30 AU$26.22 Million
≈ $18.55 Million
AU$-6.20 Million
≈ $-4.39 Million
-0.237x +46.61%
2007-06-30 AU$20.54 Million
≈ $14.53 Million
AU$-9.10 Million
≈ $-6.44 Million
-0.443x -66.55%
2006-06-30 AU$11.97 Million
≈ $8.47 Million
AU$-3.18 Million
≈ $-2.25 Million
-0.266x -747.50%
2005-06-30 AU$19.26 Million
≈ $13.63 Million
AU$-604.81K
≈ $-427.94K
-0.031x --

About Mesoblast Ltd

AU:MSB Australia Biotechnology
Market Cap
$1.95 Billion
AU$2.75 Billion AUD
Market Cap Rank
#6400 Global
#148 in Australia
Share Price
AU$2.13
Change (1 day)
+3.40%
52-Week Range
AU$1.57 - AU$3.07
All Time High
AU$5.21
About

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more